Posted on Jun 10, 2021 in the
Class actions, drug and medical device disputes
Johnson and Johnson Talc Powder attorneys call 954-384-6114.
Johnson & Johnson, one of the largest pharmaceutical companies in the US, was dismissed its appeal just last week after the Supreme Court refused to review a lower court ruling that a group of women Johnson & Johnson was after the development of Ovaries had a $ 2 billion judgment awarding cancer they claim was due to asbestos in the company’s talcum powder. The talc-based powder, Johnson’s Baby Power, has been sold for more than 100 years as talc is considered to be one of the softest minerals that reduces friction and has significant ability to absorb oils and odors. This brings Johnson and Johnson one step closer to final global agreement.
Nowhere else to go
Johnson & Johnson’s encounter with the United States Supreme Court is not the first attempt to challenge the ruling. In July 2018, a Missouri district court first sentenced Johnson & Johnson to pay $ 4.69 billion to 22 women who developed ovarian cancer and used Johnson & Johnson talcum powder. Johnson & Johnson then appealed the $ 4.69 billion ruling in hopes of overturning the Missouri District Court’s decision, which upheld the July 2018 jury verdict, but the payout was 2.12 Billions of dollars reduced.
The Missouri Court of Appeals reduced the verdict to $ 2.12 billion after dismissing some plaintiffs; However, it stuck to the result of the trial, as the court found it to be “extremely reprehensible” [Johnson & Johnson’s] Behavior. ”The Missouri Court of Appeals also upheld Johnson & Johnson’s decades of exposure to asbestos after plaintiffs presented evidence showing Johnson & Johnson“ knew about the danger of asbestos ”, as the United States’ youngest Supreme Court refused to look into this case and there are no other legal remedies, Johnson & Johnson is likely to prepare a settlement.
A known threat
Asbestos is and has been known for some time by the Department of Health and the EPA as a “known human carcinogen”. The International Agency for Research on Cancer has published confirmatory conclusions and reported an association between asbestos and mesothelioma and ovarian cancer. Presumably because of the known carcinogenic risk, the FDA tested a Johnson & Johnson baby powder bottle for asbestos in 2019. After the FDA notified Johnson & Johnson of the positive results, the company issued a voluntary “caution” recall of 33,000 bottles. That recall caused other retailers to take all Johnson baby powder off their shelves, presumably adding to the pressure that eventually led Johnson & Johnson to stop selling its iconic talc-based baby powder in North America in May 2020.
Time is of the essence
Johnson & Johnson recently allocated $ 3.9 billion in consumer health litigation costs allegedly “mostly talc-related reserves and certain settlements”. Johnson & Johnson’s January 3, 2021 annual report, cited in the baby powder case, admits that settlements or judgments may require “substantial sums” to be paid. With the recent ruling by the United States Supreme Court, Johnson & Johnson may have no choice but to reach a comprehensive settlement soon, which is why you must act now. If you have ovarian cancer, fallopian tube cancer, or mesothelioma and have used Johnson & Johnson talcum powder, you may be eligible for financial compensation.
Our team at Oppenheim Law is aware of the emotional stress these complications can place on families. For this reason, our law firm provides a team of professionals who are dedicated to representing our clients.
Please don’t hesitate to call us at (954) 384-6114 ASAP. You can also contact us at firstname.lastname@example.org or chat with us at www.oppenheimlaw.com so that we can inform you of your statutory rights so that you can receive the compensation you are entitled to. Again, time is of the essence.
Oppenheimer Law | Johnson and Johnson Talcum Powder Lawsuit
2500 Weston Road # 209
Fort Lauderdale, FL 33331
Originally published at: https://www.oppenheimlaw.com/baby-powder-lawsuit-whats-next-after-supreme-courts-denial-of-review/